Lina-gliptin / Metformin Tablets 2.5/500 mg

Adult dose

This medication is administered twice daily with meals. To reduce gastrointestinal side effects associated with Metformin, dosage increases should be gradual. 1. If not currently receiving treatment with Metformin: The initial dose is 2.5/500 mg of this medication, taken twice daily, with potential increment to 2.5/1000 mg, one tablet twice daily. 2. For patients converting from a combination therapy of Lina-gliptin and Metformin: Patients switching to this medication from the combination therapy should continue to take the same doses of Lina-gliptin and Metformin they were previously taking as the initial dosage. 3. If adequate blood sugar control cannot be achieved with insulin and Metformin: The initial dose of this medication could be considered as Lina-gliptin 2.5 mg twice daily (total daily dose of 5 mg) and should be similar to the previously administered Metformin dose. When this medication is co-administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (refer to precautions for careful administration to the following patients). There have been no studies conducted reviewing the safety and efficacy of switching patients treated with other oral antidiabetic agents to this medication. Any changes in type 2 diabetes treatment regimens may result in changes in blood sugar control and appropriate monitoring should be maintained. For patients with renal impairment: This medication may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate [eGFR] 45≤~<60 mL/min/1.73 m2) and without other symptoms that may increase the risk of lactic acidosis, the following dosage adjustments can be made. The starting dose of Metformin is 500 mg or 850 mg once daily; this medication should not be initiated in these patients. The maximum recommended dose of Metformin is 500 mg twice daily. Kidney function must be closely monitored every 3 to 6 months. If CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2 indicates declining renal function, the medication must be discontinued immediately. For patients with liver impairment: This medication should not be given to patients with liver dysfunction due to the Metformin content (refer to precautions regarding patients not to use).

This medication can cause serious side effects, such as lactic acidosis, and should not be administered to patients with poor kidney function, heart or liver impairment, or those suffering from acute infections or dehydration. Additionally, it is advisable for pregnant or breastfeeding women to avoid taking this medication. Since there is a risk of hypoglycemia, patients taking this medication along with insulin or sulfonylureas should regularly monitor their blood sugar levels and adjust their dosage as needed. Elderly patients with reduced kidney function should also undergo regular kidney function tests, and dosage adjustments should be made based on their condition. During the use of this medication, rare side effects such as acute pancreatitis or bullous pemphigoid may occur, so if abdominal pain or unusual skin symptoms arise, it is essential to consult a physician immediately. Also, this medication may reduce vitamin B12 levels, therefore, it is recommended to regularly check for vitamin B12 deficiency during long-term use. This medication may interact with other drugs, especially those affecting kidney function, so consultation with a physician is necessary when taking them together. The use of this medication should be temporarily discontinued before and after surgery or radiological examinations, and can be resumed only after kidney function has returned to normal. Lastly, this medication should be kept out of reach of children and stored away from moisture.

Serious side effects

• Lactic acidosis
• urticaria
• angioedema
• pancreatitis
• bullous pemphigoid
• rash
• liver dysfunction
• hepatitis
• severe arthralgia
• acute pancreatitis

Mild side effects

• Nasopharyngitis
• hypersensitivity
• angioedema
• hypoglycemia
• taste disturbance
• cough
• decreased appetite
• diarrhea
• constipation
• nausea

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. It is also best to maintain room temperature between 1 and 30 degrees Celsius. Proper storage conditions will help maintain the medication's effectiveness.

Appearance

Bright yellow, biconvex, oval, film-coated tablet

Package unit

10 tablets/bottle, 30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle, 30 tablets/box (10 tablets/PTP×3)